LBH deficiency influences the therapeutic effects of regulatory B cells through the regulation of IL-10 production via the Rap1 pathway

  • Cell Biosci. 2026 May 24;16(1):79. doi: 10.1186/s13578-026-01582-3.
Weijia Bao  #  1 Ke Hu  #  1 Yuan Qu  1 Yihong He  1 Xiaotong Zhu  1 Yuping Zhang  1 Yage Tian  1 Ligang Jie  2 Qinghong Yu  3
Affiliations
  • 1. Department of Rheumatology and Clinical Immunology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510280, Guangdong, China.
  • 2. Department of Rheumatology and Clinical Immunology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510280, Guangdong, China. [email protected].
  • 3. Department of Rheumatology and Clinical Immunology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510280, Guangdong, China. [email protected].
  • # Contributed equally.
Abstract

Regulatory B cells (Bregs) are immune cells that affect the autoimmune response by producing interleukin (IL)-10, but the molecular mechanism affecting Breg differentiation and IL-10 production is not clear. Our study found that mice with limb bud and limb-bud and heart (LBH) gene deficiency in dextran sulfate sodium (DSS)-induced colitis showed severe colitis but exhibited an increase in Bregs in mesenteric lymph nodes and the spleen. LBH deficiency increased IL-10 production and expression of the surface molecule CD24 in B cells. Mechanistically, Ras-proximate-1 (Rap1) signaling pathway activation in LBH-deleted B cells and simultaneous inhibition of Rap 1 activation or extracellular signal-related kinase (ERK) phosphorylation reduced Breg differentiation among B cells. Furthermore, LBH deficient B cells showed a more significant therapeutic effect on DSS-induced colitis. Taken together, the results of this study revealed the mechanism by which LBH affects IL-10 production during Breg differentiation and that LBH deficiency enhanced the therapeutic efficacy of B cells for DSS-induced colitis.

Keywords
Inflammatory bowel disease; Interleukin-10; Limb-bud and heart; Ras-proximate-1 pathway; Regulatory B cells.
Products
Inhibitors & Agonists
Other Products